| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Ron H J Mathijssen | |
| Stijn L W Koolen | |||
| Carin C D van der Rijt | |||
| Maarten L Zandvliet | |||
| Evelien J M Kuip | |||
| P2860 | cites work | The Concise Guide to PHARMACOLOGY 2015/16: Enzymes | Q28552567 |
| The Concise Guide to PHARMACOLOGY 2015/16: Transporters | Q28552572 | ||
| The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands | Q28603128 | ||
| The Concise Guide to PHARMACOLOGY 2015/16: Overview | Q30488640 | ||
| Breakthrough pain: definition, prevalence and characteristics | Q33435886 | ||
| Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl | Q33834608 | ||
| Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control | Q34481299 | ||
| The influence of sex on pharmacokinetics | Q35049301 | ||
| Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil | Q35092352 | ||
| Absorption and tolerability of fentanyl buccal soluble film (FBSF) in patients with cancer in the presence of oral mucositis | Q35221603 | ||
| Support of the metabolic response to burn injury | Q35796326 | ||
| Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate | Q35871326 | ||
| Influence of age on the pharmacokinetics and pharmacodynamics of oral transmucosal fentanyl citrate | Q35871331 | ||
| Treatment with subcutaneous and transdermal fentanyl: results from a population pharmacokinetic study in cancer patients. | Q36688467 | ||
| Fentanyl for breakthrough pain: a systematic review | Q37907299 | ||
| Determining the optimal dose in the development of anticancer agents | Q38198948 | ||
| A Systematic Review of Prospective Studies Reporting Adverse Events of Commonly Used Opioids for Cancer-Related Pain: A Call for the Use of Standardized Outcome Measures. | Q38519237 | ||
| Fentanyl pharmacokinetics is not dependent on hepatic uptake by organic anion-transporting polypeptide 1B1 in human beings | Q39182431 | ||
| Formulations of fentanyl for the management of pain | Q39293912 | ||
| Inter- and intra-individual variability in transdermal fentanyl absorption in cancer pain patients. | Q39362437 | ||
| Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients | Q39364004 | ||
| Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control | Q39459785 | ||
| Pharmacokinetics of fentanyl during constant rate i.v. infusion for the relief of pain after surgery | Q39541998 | ||
| Clinical pharmacokinetics of fentanyl and its newer derivatives. | Q40115663 | ||
| Life-threatening coma and full-thickness sunburn in a patient treated with transdermal fentanyl patches: a case report | Q40279485 | ||
| Case report: delirium due to a diltiazem-fentanyl CYP3A4 drug interaction | Q42791386 | ||
| A review of the use of fentanyl analgesia in the management of acute pain in adults | Q43070474 | ||
| Fentanyl transdermal absorption linked to pharmacokinetic characteristics in patients undergoing palliative care | Q43185208 | ||
| Population pharmacokinetics of fentanyl in healthy volunteers. | Q43673466 | ||
| Opioid overdose in a patient using a fentanyl patch during treatment with a warming blanket | Q43721196 | ||
| Itraconazole-fentanyl interaction in a cancer patient | Q44233589 | ||
| Opioid-induced respiratory depression resulting from transdermal fentanyl-clarithromycin drug interaction in a patient with advanced COPD. | Q44342955 | ||
| Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4. | Q44343799 | ||
| The pharmacokinetics of transdermal fentanyl delivered with and without controlled heat | Q44658602 | ||
| Serum concentration of fentanyl during conversion from intravenous to transdermal administration to patients with chronic cancer pain | Q45759953 | ||
| Transdermal fentanyl in cachectic cancer patients. | Q46012125 | ||
| Evaluation of diurnal variation in fentanyl clearance | Q46591983 | ||
| Pharmacokinetics of fentanyl in the elderly | Q46733636 | ||
| Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression | Q46906576 | ||
| Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl | Q46911536 | ||
| Pharmacokinetic interaction of intravenous fentanyl with ketoconazole | Q47752672 | ||
| Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study | Q47919321 | ||
| Impact of CYP3A5*3 on plasma exposure and urinary excretion of fentanyl and norfentanyl in the early postsurgical period | Q47933153 | ||
| Pharmacokinetics and dose proportionality of fentanyl sublingual spray: a single-dose 5-way crossover study | Q48015149 | ||
| Impact of allergic rhinitis and its treatment on the pharmacokinetics of nasally administered fentanyl | Q48030393 | ||
| Population pharmacokinetics of transdermal fentanyl in patients with cancer-related pain | Q48149163 | ||
| Impact of CYP3A5 and ABCB1 gene polymorphisms on fentanyl pharmacokinetics and clinical responses in cancer patients undergoing conversion to a transdermal system | Q48192111 | ||
| Active transport of fentanyl by the blood-brain barrier. | Q48228612 | ||
| Randomized 5-treatment crossover study to assess the effects of external heat on serum fentanyl concentrations during treatment with transdermal fentanyl systems. | Q48235000 | ||
| The population pharmacokinetics of fentanyl in patients undergoing living-donor liver transplantation | Q48241556 | ||
| Absorption of fentanyl from fentanyl buccal tablet in cancer patients with or without oral mucositis: a pilot study | Q48572563 | ||
| Fentanyl clearance and volume of distribution are increased in patients with major burns | Q48606918 | ||
| Possible fluconazole-fentanyl interaction-a case report | Q48692216 | ||
| Assessing the impact of heat on the systemic delivery of fentanyl through the transdermal fentanyl delivery system | Q48892222 | ||
| Breakthrough pain: characteristics and impact in patients with cancer pain. | Q51089873 | ||
| Impaired memory and behavioral performance with fentanyl at low plasma concentrations. | Q51130059 | ||
| Ritonavir's role in reducing fentanyl clearance and prolonging its half-life. | Q51441513 | ||
| The CYP 3A4 inhibitor itraconazole has no effect on the pharmacokinetics of i.v. fentanyl. | Q51478388 | ||
| Heat-related toxicity with the fentanyl transdermal patch. | Q51487004 | ||
| Perioperative pharmacokinetics of transdermal fentanyl in elderly and young adult patients. | Q51491969 | ||
| Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions. | Q51536172 | ||
| Fentanyl pharmacokinetics in patients undergoing renal transplantation. | Q51539421 | ||
| Transdermal fentanyl disposition in elderly subjects. | Q51645730 | ||
| Age and fentanyl pharmacokinetics. | Q51857997 | ||
| Fentanyl Pharmacokinetics in Awake Volunteers | Q51872910 | ||
| Pharmacokinetics of high-dose fentanyl. A study in patients undergoing cardiac surgery. | Q51874913 | ||
| Intravenous fentanyl kinetics. | Q51875549 | ||
| Epidemiology and Pattern of Care of Breakthrough Cancer Pain in a Longitudinal Sample of Cancer Patients | Q59649189 | ||
| Pharmacokinetic and pharmacodynamic changes in the elderly. Clinical implications | Q74798758 | ||
| Management of cancer pain | Q77769507 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| fentanyl | Q407541 | ||
| P304 | page(s) | 294-313 | |
| P577 | publication date | 2016-10-29 | |
| P1433 | published in | British Journal of Clinical Pharmacology | Q176044 |
| P1476 | title | A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients | |
| P478 | volume | 83 |
| Q90184953 | Characterizing Fentanyl Variability Using Population Pharmacokinetics in Pediatric Burn Patients |
| Q90376886 | Does transdermal fentanyl work in patients with low BMI? Patient-reported outcomes of pain and percent pain relief in cancer patients on transdermal fentanyl |
| Q50052624 | Effect of creatine phosphate sodium on bispectral index and recovery quality during the general anaesthesia emergence period in elderly patients: A randomized, double-blind, placebo-controlled trial |
| Q55382249 | Effects of smoking and body mass index on the exposure of fentanyl in patients with cancer. |
| Q58118095 | Impact of CYP3A4*1G Polymorphism on Fentanyl Analgesia Assessed by Analgesia Nociception Index in Chinese Patients Undergoing Hysteroscopy |
| Q98892340 | Indian Society for Study of Pain, Cancer Pain Special Interest Group Guidelines on Pharmacological Management of Cancer Pain (Part I) |
| Q53681128 | Influence of aprepitant and localization of the patch on fentanyl exposure in patients with cancer using transdermal fentanyl. |
| Q53682973 | Is there a role for pharmacogenetics in the dosing of fentanyl? |
| Q64071994 | Metabolic Pathways and Potencies of New Fentanyl Analogs |
| Q90641478 | Minor contribution of cytochrome P450 3A activity on fentanyl exposure in palliative care cancer patients |
| Q47341348 | Not so patchy story of attempted suicide…leading to 24 hours of deep sleep and survival! |
| Q64891530 | Pain polymorphisms and opioids: An evidence based review. |
| Q59800576 | Pharmacokinetics of Sublingually Delivered Fentanyl in Head and Neck Cancer Patients Treated with Curatively Aimed Chemo or Bioradiotherapy |
| Q99725553 | Physiologically-Based Pharmacokinetic (PBPK) Modeling Providing Insights into Fentanyl Pharmacokinetics in Adults and Pediatric Patients |
| Q98197851 | Safety, Tolerability, and Dose Proportionality of a Novel Transdermal Fentanyl Matrix Patch and Bioequivalence With a Matrix Fentanyl Patch: Two Phase 1 Single-Center Open-Label, Randomized Crossover Studies in Healthy Japanese Volunteers |
Search more.